Dr. John P. Donoghue Wins Germany's Top Neuroscience Honor for Development of Cyberkinetics' BrainGate System

Business Wire, August 20, 2007

Annual Zulch Prize for neurological research is administered by the Max Planck Society.

Cyberkinetics' BrainGate technology enables paralyzed people to operate devices using thought alone.

FOXBOROUGH, Mass. -- Cyberkinetics Neurotechnology Systems, Inc. (OTCBB:CYKN; "Cyberkinetics") announced that John P. Donoghue, Ph.D., Cyberkinetics' Chief Scientific Officer and director of the Brain Science Program at Brown University, will be awarded the K. J. Zulch Prize, Germany's highest honor for neurological research. Dr. Donoghue is being recognized for his groundbreaking research on the BrainGate Neural Interface System (BrainGate), a technology designed to enable severely paralyzed people to use thought alone to operate a variety of assistive devices, such as a computer cursor and a wheelchair.

The Zulch Prize, which is bestowed by the Gertrud Reemtsma Foundation through the Max Planck Society, is awarded annually to two scientists for outstanding achievements. This year, Dr. Donoghue will share the award, along with a cash prize of 50,000 Euros (approximately $68,300), with Graeme Clark, developer of the cochlear implant (bionic ear). The prize will be awarded at a ceremony on August 31, 2007, in Cologne, Germany.

Previous recipients of the Zulch Prize include: Nobel Laureate Stanley B. Prusiner, M.D., who discovered the infectious proteins called prions; Nikos K. Logothetis, Ph.D., who pioneered functional magnetic resonance imaging in vision research; Samuel F. Berkovic, M.D., who determined the genetic basis for epilepsy; and Fred H. Gage, Ph.D., who spearheaded research that showed human beings are capable of growing new nerve cells throughout life.

"We congratulate John for this well deserved international recognition of his pioneering research, which has led to the development of Cyberkinetics' BrainGate program," stated Timothy R. Surgenor, Cyberkinetics' President and Chief Executive Officer. "John's efforts to bring cutting-edge, basic science to bear on the lives of the severely disabled are an inspiration to all of us at Cyberkinetics."

Dr. Donoghue is the Henry Merritt Wriston Professor at Brown University. A leader in neuroprosthesis research and development, his work centers on understanding how networks of neurons within the brain process complex information that results in skilled voluntary movement.

About the BrainGate Neural Interface System

The BrainGate Neural Interface System is a proprietary, investigational brain-computer interface (BCI) that consists of an internal sensor to detect brain cell activity and external processors that convert these brain signals into a computer-mediated output under the person's own control. The sensor is a tiny silicon chip about the size of a baby aspirin with one hundred electrodes, each thinner than a human hair, that can detect the electrical activity of neurons. The sensor is implanted on the surface of the area of the brain responsible for movement, the motor cortex. A small wire connects the sensor to a pedestal that is placed on the skull, extending through the scalp. An external cable connects the pedestal to a cart containing computers, signal processors and monitors that enable the study operators to determine how well study participants can control devices driven by their neural output - that is, by thought alone.

The ultimate goal of the BrainGate System development program is to create a safe, effective and unobtrusive universal operating system that will enable those with motor impairments resulting from a variety of causes to quickly and reliably control a wide range of devices, including computers, assistive technologies and medical devices, simply by using their thoughts. The fundamental groundwork for this human clinical work was conducted in the Donoghue lab at Brown University and made possible by preclinical funding from the National Institute of Neurological Disorders and Stroke.

About the Max Planck Society

The Max Planck Society for the Advancement of Science is an independent, non-profit research organization. Founded on February 26, 1948, the primary goal of the Max Planck Society is to perform basic research in the interest of the general public in the natural sciences, life sciences, social sciences, and the humanities. Since its founding, the Max Planck Society boasts 16 Nobel Prize recipients. Additional information is available at http://www.mpg.de/english/portal/index.html.> About Cyberkinetics Neurotechnology Systems, Inc.

Cyberkinetics Neurotechnology Systems, Inc., a leader in the neurotechnology industry, is developing neural stimulation, sensing and processing technology to improve the lives of those with severe paralysis resulting from spinal cord injuries, neurological disorders and other conditions of the nervous system. Cyberkinetics' product development pipeline includes: Andara[TM] OFS[TM] Therapy for acute spinal cord injury, an investigative device designed to stimulate nerve repair and restore sensation and motor function; the BrainGate System, an investigative device designed to provide communication and control of a computer, assistive devices, and, ultimately, limb movement; and a pilot program in the detection and prediction of seizures due to epilepsy. Additional information is available at Cyberkinetics' website at http://www.cyberkineticsinc.com.